HealthBanks USA Inc. Patent applications |
Patent application number | Title | Published |
20120213811 | CHIMERIC HIV FUSION PROTEINS AS VACCINES - A method for treating HIV infection is disclosed. The method comprises administering to a patient in need thereof a therapeutically effective amount of a fusion protein comprising: a) a | 08-23-2012 |
20110027311 | COMBINATION OF PROTEIN VACCINE AND MESENCHYMAL STEM CELLS FOR TREATING CANCER - A method for inhibiting growth and/or metastasis of a tumor in a mammal is disclosed. The method comprises administering to a mammal in need thereof an effective amount of stem cells comprising a transgene encoding at least one oncogenic protein, wherein the stem cells are immortal and show no signs of neoplastic transformation, and administering to the mammal a vaccine composition comprising an effective amount of at least one immunogenic protein capable of eliciting at least one antibody specific against the at least one oncogenic protein, and thereby inhibiting growth and/or metastasis of a tumor in the mammal. A therapeutic kit for inhibiting growth and/or metastasis of a tumor in a mammal is also disclosed. | 02-03-2011 |
20090203884 | CHIMERIC HIV FUSION PROTEINS AS VACCINES - A chimeric fusion protein useful as an immunogen for inducing HIV antigen-specific immune responses contains a first polypeptidyl region and a second polypeptidyl region. The first polypeptidyl region includes a Pseudomonas Exotoxin A (PE) binding domain and a PE translocation domain. The second polypeptidyl region includes (i) a first peptidyl segment containing a fragment of gp120 C1 domain, located at the N-terminus of the second peptidyl region; (ii) a second peptidyl segment containing a fragment of gp120 C5 domain, located at the C-terminus of the first peptidyl segment; and (iii) a third peptidyl segment containing a fragment of gp41, located at the C-terminus of the second peptidyl segment. The second polypeptidyl region contains an antigenic determinant specific to one subtype of HIV. An intermediate polypeptide containing a non-Env, HIV antigenic determinant selected from Gag24, Nef, Tat and Rev may be included. | 08-13-2009 |